These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Shak S Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196 [TBL] [Abstract][Full Text] [Related]
6. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Albanell J; Codony J; Rovira A; Mellado B; Gascón P Adv Exp Med Biol; 2003; 532():253-68. PubMed ID: 12908564 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005 [TBL] [Abstract][Full Text] [Related]
8. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. Spector NL; Blackwell KL J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552 [TBL] [Abstract][Full Text] [Related]
9. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer. Morris SR; Carey LA Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127 [TBL] [Abstract][Full Text] [Related]
10. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Menendez JA; Vellon L; Lupu R Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086 [TBL] [Abstract][Full Text] [Related]
11. From HER2 to herceptin. Mokbel K; Hassanally D Curr Med Res Opin; 2001; 17(1):51-9. PubMed ID: 11464447 [TBL] [Abstract][Full Text] [Related]
12. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Yeon CH; Pegram MD Invest New Drugs; 2005 Oct; 23(5):391-409. PubMed ID: 16133791 [TBL] [Abstract][Full Text] [Related]
14. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer]. Dank M Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175 [TBL] [Abstract][Full Text] [Related]
15. Progression and treatment of HER2-positive breast cancer. Davoli A; Hocevar BA; Brown TL Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739 [TBL] [Abstract][Full Text] [Related]
16. [Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance]. Dieras V; Vincent-Salomon A; Degeorges A; Beuzeboc P; Mignot L; de Cremoux P Bull Cancer; 2007 Mar; 94(3):259-66. PubMed ID: 17371768 [TBL] [Abstract][Full Text] [Related]
17. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells. Marches R; Uhr JW Int J Cancer; 2004 Nov; 112(3):492-501. PubMed ID: 15382077 [TBL] [Abstract][Full Text] [Related]
18. [Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?]. Beuzeboc P; Scholl S; Garau XS; Vincent-Salomon A; Cremoux PD; Couturier J; Palangié T; Pouillart P Bull Cancer; 1999 Jun; 86(6):544-9. PubMed ID: 10417428 [TBL] [Abstract][Full Text] [Related]
19. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Goldenberg MM Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534 [TBL] [Abstract][Full Text] [Related]
20. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale. Esteva FJ; Pusztai L Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]